Skip to main content

Developing therapies to target multiple immune pathways

17 Jun 2024
Salon D
  • Which formats have better clinical success – VHH vs Ig-like vs non-Ig-like molecules?
  • Immunogeneicity concerns for non-Ig-like formats
  • Manufacturing challenges especially for multi-specific antibodies
  • How will Cryo-EM and AI/ML assist in designing future bispecific & multispecific antibodies?
  • Future of IgM-like multi-specific antibodies: Would it overcome potential immunogeneicity concern? What about manufacturing challenges?
Industry Expert
Vishal Kamat, Senior Director Protein Sciences - Ampersand Biomedicine